taselisib taselisib taselisib (development code: gdc-0032) is a former cancer drug candidate that was in development by roche. it is a small molecule phosphoinositide 3-kinase inhibitor targeting the pi3k isoform p110α (pik3ca). taselisibclinical dataatc codenoneidentifiers iupac name 2--2-methylpropanamide cas number1282512-48-4pubchem cid51001932chemspider29315044uniil08j2o299mkeggd11774chemblchembl2387080comptox dashboard (epa)dtxsid00155842 chemical and physical dataformulac24h28n8o2molar mass460.542 g·mol−13d model (jsmol)interactive image smiles cc1=nn(c(=n1)c2=cn3ccoc4=c(c3=n2)c=cc(=c4)c5=cn(n=c5)c(c)(c)c(=o)n)c(c)c inchi inchi=1s/c24h28n8o2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14h,8-9h2,1-5h3,(h2,25,33)key:beuqxvwxfdosaq-uhfffaoysa-n roche announced in june 2018 that there would be no further development of taselislib following the top line results of the phase iii "sandpiper" study. currently running clinical trials were continued for patients exhibiting benefit.